Jean-Jacques Kiladjian/LinkedIn
Dec 8, 2025, 14:46
Jean Jacques Kiladjian Presents 1st Results of the ROP-ET Study at ASH25
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”Proud to have presented at American Society of Hematology ASH25 , on behalf of my co-investigators from 10 European countries, the first results of the ROP-ET study showing that ropeginterferon-alpha 2b is also an effective and safe treatment for patients with essential thrombocythemia ET who have no other therapeutic option.
At 12 months: 65% of durable (>3 months) complete hematologic response, no disease progression, only 1.5% of major thrombotic events, symptoms improvement in 62% of patients.”
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment